Oncolytics Biotech Inc. Announces Issuance of Patent for Treatment of Cellular Proliferative Disorders
Advertisement
Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,252,817 entitled "viruses for the Treatment of Cellular Proliferative Disorders." The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers).
"This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.